Seminar in Medicine, 08.12.2017, Rodrigo Dienstmann, MD

Author: KUSOM
Time: 11:00
Location: ENG 208



Friday, December 8th, 2017


Speaker        : Rodrigo Dienstmann, MD / Vall d´Hebron Institute of Oncology / Oncology data Science Group
Title             : Precision Oncology: Hope and Hype
Time            : 11.00 (Refreshments will be served at 10:45)
Place            : ENG 208                                          

TelePresence  : AH Dean's Office / KUH 9th floor Meeting Room

Precision Oncology: Hope and Hype

Precision oncology pairs tumor and/or germline genome sequencing with the latest insights into cancer biology to prioritize alterations that can be directly matched to targeted therapies. Many challenges exist for implementing precision oncology, but knowledge gaps in the interpretation of cancer variants and off-label access to approved agents or experimental drugs in clinical trials are major barriers faced by medical oncologists. Most cancer variants are of unknown clinical significance and tumors frequently harbor multiple potentially druggable alterations, highlighting the complexity of the genomic landscape and difficulties for treatment prioritization. A “cancer genome interpreter” must deal with the huge amount of unstructured information on effectiveness of therapies matched to driver alterations; this information is being constantly generated by clinical trials and preclinical experiments. Moreover, potential and confirmed germline genomic events identified during tumor and/or normal DNA sequencing may pose significant challenges for oncologists who are not prepared to handle incidental findings that have both therapeutic impact for the individual cancer patient and clinical implications for at-risk family members. Molecular tumor boards can bridge this gap by facilitating the exchange of information among a wide range of experts (medical oncologists, cancer geneticists and biologists, molecular pathologists, genetic counselors, bioinformaticians, and others). In my talk, I will review existing international precision oncology initiatives and use Vall d’Hebron Institute of Oncology’s experience over the last decade to showcase obstacles for implementation and future prospects.